Stay updated on HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Sign up to get notified when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.

Latest updates to the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page
- Check2 days agoNo Change Detected
- Check8 days agoNo Change Detected
- Check16 days agoChange DetectedRevision updated from v3.6.5 to v3.6.6. This reflects a version bump for the page rather than a substantive change to study details.SummaryDifference0.1%

- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedThe page's revision tag was updated from v3.6.4 to v3.6.5, representing a small backend/content management update.SummaryDifference0.1%

- Check51 days agoChange DetectedThe page’s revision metadata updated from v3.6.3 to v3.6.4, indicating a new version of the page.SummaryDifference0.1%

- Check72 days agoChange DetectedRevision tag updated from v3.6.2 to v3.6.3, reflecting a minor update to the study record documentation.SummaryDifference0.1%

- Check79 days agoChange DetectedThe revision tag in the page footer was updated from v3.6.0 to v3.6.2, indicating a newer platform release.SummaryDifference0.1%

- Check94 days agoChange DetectedRecruitment status is updated to indicate enrollment is closed. New help pages and navigation tools were added to guide users on reading the study record and joining, with a formatting update to the Intervention/Treatment label.SummaryDifference0.4%

Stay in the know with updates to HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial
Enter your email address, and we'll notify you when there's something new on the HIV+ Safety of High-dose Rifapentine-Isoniazid DDI Clinical Trial page.